UB Internal Medicine

This account is maintained by our Chief Residents from the University at Buffalo Internal Medicine Program. Follow for more info and medical education!

[UB Internal Medicine @UBIMResidency]

🎉 HUGE welcome to our Incoming Internal Medicine Residency Class! 🩺

We are thrilled to welcome this talented group of future internists to our family!

#MedTwitter #MedX #InternalMedicine #ResidencyMatch #Match2026 #IMProud @Jacobs_Med_UB @UBuffalo @Inside_TheMatch

[Sawyer Bawek, DO @sawyer_bawek]

#HemOnc #Match Tips Part 4️⃣ Interview Prep

🔑 Prepare a polished 60-90 sec “Tell Me About Yourself”
🔑 Review application thoroughly
🔑 Research programs website, videos, interviewers, etc
🔑 Prepare 4-5 thoughtful program specific questions
#OncTwitter #MedTwitter #MedX #ERAS

[Sawyer Bawek, DO @sawyer_bawek]

⭐️#HemOnc #ERAS Tips

🔑Don’t compare yourself to others, everyone’s journey is different
🔑Every program looks for different things in applicants
🔑No interview invite≠you’re not a strong candidate. You may simply not be the best fit
#MedTwitter #OncTwitter #Match @ASCOTECAG

[Sawyer Bawek, DO @sawyer_bawek]

⭐️To all the #HemOnc #Match applicants who submitted their #ERAS applications, congrats!

👉Make sure to take some time and reflect, be proud of all you accomplished.

🔑Most programs have not even started reviewing applications yet or are beginning.
#MedTwitter #OncTwitter

[Sawyer Bawek, DO @sawyer_bawek]

Excited to announce that I've been selected for the @doximity 2026–2027 AI
Fellowship!

Excited to learn more on how to advance clinician/patient education, streamline clinical workflows, and advance research for improved patient outcomes. #Doximity #doximityfellow #OncTwitter

[Sawyer Bawek, DO @sawyer_bawek]

⭐️#Fellowship Application Essentials: Program Director Tips from #ASCO26

🔗Full article summary 👇

#ASCOConnection #ASCO
#OncTwitter #MedTwitter #MedEd
@ASCOTECAG @hemeoncfellow @HemOncFellows #Match #Match2026 @IMG_Oncologists @CleClinicMD

[Sawyer Bawek, DO @sawyer_bawek]

💥#Fellowship Application Essentials: Program Director Tips from #ASCO26 Trainee & Early Career Lounge Panel!

⭐️Key pearls for #HemOnc applicants!

#ASCOConnection #ASCO @ASCO
#OncTwitter #MedTwitter #MedEd
@ASCOTECAG @hemeoncfellow @HemOncFellows

https://t.co/6rUCxmT8OI

[OncUpdates @OncUpdates]

⭐️Talquetamab Side Effects: Management & Counseling 🩸

🎙️ @sawyer_bawek & @hhashmi87 🗣️
✅ Skin/nail: topical therapies & care routines
✅ Oral/dysgeusia: counseling & dietitian support
✅ CRS & neurotoxicity pearls
#OncTwitter #mmsm #HemOnc #ASCO26

🎥👇
https://t.co/YGAJtBGbXW

[Sawyer Bawek, DO @sawyer_bawek]

Excited to get to work with @JCOOP_ASCO for the JCO Journals Editorial Fellowship! Also excited to get to work with 🤩@KalantriShreyas throughout the year!

@CleClinicMD #OncTwitter #Oncology #MedTwitter #MedX #MedEd #HemOnc @ASCOTECAG @JCO_ASCO #PeerReview @HemOncFellows

[Sarbajit Mukherjee @Sarbaji85064063]

As cancer immunotherapy moves beyond PD-1/PD-L1 and CTLA-4, we must recognize that each new immune target may have its own toxicity fingerprint.
Kudos to @waraonc23 on publishing this important systematic review and meta-analysis in JNCI Cancer Spectrum.
Across 27 trials and 3,946 patients, the key findings were:
• LAG-3–directed therapy was associated with increased adrenal insufficiency, and arthralgia.
• TIGIT blockade was associated with increased rash, without a significant increase in severe adverse events.
• Pooled analyses identified additional toxicity signals: pneumonitis and hepatitis with TIM-3, rash with CD40 agonists, and diarrhea with OX40 agonists.
The key message for clinicians and drug developers: emerging checkpoints should not be assumed to share the safety profile of established immunotherapies. Target-specific monitoring must become part of trial design and clinical implementation.
Congratulations, Fuji, @MrinaliniR57669 and to our entire collaborative team!
@BrainTumorDoc @BaptistHealthSF @BHAcademics @MiamiCancerInst @RoswellPark @RoswellHemOnc @UBIMResidency @OncBrothers @OncoAlert @OncUpdates @OxUniPress
https://t.co/rJYZtIxcha

[Sawyer Bawek, DO @sawyer_bawek]

This one is special, getting to interview my cofellow @AgrimaMianMD 🙌

👉Listen in to hear why national conferences like @ASCO @ASH_hematology are so important for trainees!

#ASCO26 #OncTwitter #MedTwitter #HemOnc #MedEd @CleClinicMD @ASCOTECAG @HemOncFellows @hemeoncfellow

[Sawyer Bawek, DO @sawyer_bawek]

Grateful to share the stage for my first podium experience with my mentor since intern year of residency @Sarbaji85064063!

Another highlight is getting to meet and hear outstanding presentations from 🤩@CathyEngMD @DrShubhamPant @Deebacca!

@binaytara #OncTwitter #MedTwitter

[OncUpdates @OncUpdates]

⭐️ MajesTEC-9-Teclistamab Moving into Earlier Lines #MultipleMyeloma

✅ Strong PFS & OS improvements
✅ Deep responses (high ≥CR rates)

Excellent discussion w/@sawyer_bawek +myeloma expert @hhashmi87!
#OncTwitter #mmsm #HemOnc #ASCO26 @MSKCancerCenter
https://t.co/SNKM9AquZg

[OncUpdates @OncUpdates]

⭐️See You This Weekend! @OncBrothers

👉Upstate NY Cancer Symposium
🗓️ June 20th
📍Rochester, NY
🎙️Discussion on Standard of Care

🔗Register: https://t.co/NwZAmWCl1t

#OncTwitter #MedTwitter #MedX #HemOnc #MedEd @WilmotCancer @RoswellPark @RoswellHemOnc @PTarantinoMD

[Nour Nassour, MD @NourNassourMD]

I am extremely honored to receive the Rakesh Bidani Resident Award as I end my PGY2! So grateful for the opportunity to learn, teach, and grow every day at @UBIMResidency☺️ Looking forward to paying forward all the mentorship I have received! @IMG_Oncologists @oncodaily

[Hizra Farrukh @HizraFarrukh]

Incredibly honored and excited to receive the Intern of the Year Award!

It has been a privilege to learn and work alongside the incredible team at @UBIMResidency. Excited to embrace new challenges, pay it forward and strive for the patients and communities we serve.

[Sawyer Bawek, DO @sawyer_bawek]

🔥Exciting early signals for vopimetostat (TNG462) + daraxonrasib in MTAP-deleted #pancreatic ductal adenocarcinoma

👉In this ongoing Ph1/2 combo (2/3L setting):
‼️ORR 92%
✅DCR 100%
✅90% 6-month PFS rate in #PDAC (median PFS NR)

#OncTwitter #MedTwitter #gism #Oncology #MedX

[OncUpdates @OncUpdates]

⭐️Building off #ASCO26, exciting news in #pancreaticcancer 👇!

#OncTwitter #RASRevolution #MedTwitter #MedX #gism #Oncology #GIOnc @DanaFarber @OncBrothers @TheGutOncLab #cancerresearch #clinicaltrials

[Sawyer Bawek, DO @sawyer_bawek]

🙏I had chills watching Dr. Wolpin present this pivotal trial. He received a standing ovation mid-speech after the survival outcomes!

👏This video is an excellent breakdown, reaction, and summary. This moment can’t be talked about enough 🙌#OncTwitter #ASCO26 @ASCO #MedTwitter

[OncUpdates @OncUpdates]

🚨GAME CHANGER in #PancreaticCancer #ASCO26

🤩 Experts @DrShubhamPant @rachnatshroff @EileenMOReilly +Dr.Ko sit down w/ @OncBrothers to discuss this pivotal trial!

#OncTwitter #pcsm #gism #MedTwitter #ASCO #CancerResearch #cancer #MedEd

🔗 Full video👇
https://t.co/ItYlfiWw8T

[OncUpdates @OncUpdates]

⭐ Major Breakthrough in Pancreatic Cancer

‼️Chills from this video from yesterday’s #ASCO26 Plenary Session! Truly a moment to remember and a pivotal moment in the treatment of #pancreatcancer @ASCO @OncBrothers #OncTwitter #MedTwitter #CancerResearch

https://t.co/r1En0s5Xe7